Bubs Australia (ASX:BUB): One of the few infant formula stocks building a post-China future
Bubs Australia (ASX:BUB) navigated challenges post-pandemic, shifting focus from China to ASEAN markets and the USA. Despite boardroom turmoil and China sales disappointments, Bubs achieved growth in the USA, becoming a top 6 infant formula seller. The company aims for permanent US market access by October 2025, conducting a clinical trial to support this goal.
Reference News
Bubs Australia (ASX:BUB): One of the few infant formula stocks building a post-China future
Bubs Australia (ASX:BUB) navigated challenges post-pandemic, shifting focus from China to ASEAN markets and the USA. Despite boardroom turmoil and China sales disappointments, Bubs achieved growth in the USA, becoming a top 6 infant formula seller. The company aims for permanent US market access by October 2025, conducting a clinical trial to support this goal.